xpertsystems/hconc005-sample

HC-ONC-005是一个完全合成的胰腺导管腺癌（PDAC）队列数据集，覆盖完整的临床路径。它包括AJCC第8版分期与NCCN可切除性分类（可切除/临界可切除/局部晚期/转移性）、全面的分子分析（KRAS的7种变体、TP53、SMAD4、CDKN2A、BRCA1/2种系与BRCA2体细胞、PALB2、ATM、HRD评分、MSI状态、TMB、PD-L1、HER2、NTRK）、手术结果（Whipple/PPPD/远端/全胰腺切除术，附带ISGPF瘘管分级和ISGPS DGE分级）、胰腺手术期治疗（FOLFIRINOX/mFOLFIRINOX/Gemcitabine+NabPaclitaxel/NALIRIFOX/olaparib/pembrolizumab/sotorasib用于KRAS G12C/larotrectinib用于NTRK）、RECIST治疗反应与反应深度、CA 19-9动态与纵向轨迹面板、生存终点（OS/PFS/RFS，基于PRODIGE-4 FOLFIRINOX、MPACT、POLO、NAPOLI-3进行Weibull校准）、QoL（QLQ-C30、PAN26），并通过5个关系表（基于patient_id关联）整合。数据集设计用于分析、建模、演示和教育，同时保持100%合成性，无真实患者数据、PHI或再识别风险。样本包括500名患者的主要队列、约4,400行CA 19-9纵向面板、100行手术子集、500行分子面板和约860行治疗历史。HC-ONC-005 is a fully synthetic pancreatic ductal adenocarcinoma (PDAC) cohort dataset spanning the complete clinical pathway. It includes AJCC 8th Edition staging with NCCN resectability classification (Resectable/Borderline_Resectable/Locally_Advanced/Metastatic), comprehensive molecular profiling (KRAS with 7 variants, TP53, SMAD4, CDKN2A, BRCA1/2 germline + BRCA2 somatic, PALB2, ATM, HRD score, MSI status, TMB, PD-L1, HER2, NTRK), surgical outcomes (Whipple/PPPD/Distal/Total pancreatectomy with ISGPF fistula grading and ISGPS DGE grading), Pancreatic-Surgery-era treatment (FOLFIRINOX/mFOLFIRINOX/Gemcitabine+NabPaclitaxel/NALIRIFOX/olaparib/pembrolizumab/sotorasib for KRAS G12C/larotrectinib for NTRK), RECIST treatment response with depth-of-response, CA 19-9 dynamics with longitudinal trajectory panel, survival endpoints (OS/PFS/RFS — Weibull-calibrated to PRODIGE-4 FOLFIRINOX, MPACT, POLO, NAPOLI-3), QoL (QLQ-C30, PAN26), and is integrated through 5 relational tables joined on patient_id. The dataset is built for analytics, modeling, demos, and education while remaining 100% synthetic — no real patient data, no PHI, no re-identification risk. The sample consists of a 500-patient primary cohort, ~4,400-row CA 19-9 longitudinal panel, 100-row surgical subset, 500-row molecular panel, and ~860-row treatment history.